Back to Headlines
Business
Jun 15, 2026
Analyzed by GPT OSS 120B

Sigma Pulls Out of $10bn Boots Takeover Talks

AI Summary
Australian pharmacy group Sigma Healthcare has abandoned negotiations to buy UK retailer Boots, ending a deal valued at about $10bn. The move sparked a 6% rise in Sigma’s shares and leaves the 177‑year‑old chain in limbo as other suitors, including the Weston family, remain interested.

Australian pharmacy group Sigma Healthcare announced on Monday that it is walking away from negotiations to acquire the UK high‑street pharmacy chain Boots, ending a potential $10bn (£7bn) deal.

Sigma abandons $10bn bid for Boots

Sigma said the proposed acquisition would not meet its strategic and capital‑investment objectives, despite earlier indications that it was reviewing opportunities to create shareholder value. The company had only recently taken a controlling stake in Greenlight Healthcare, expanding its footprint in the Australian market.

Financial stakes and market reaction

  • Deal valuation: estimated at $10bn (£7bn) by the Financial Times.
  • Share price impact: Sigma shares jumped 6% on Monday.
  • Recent merger: Sigma merged with Chemist Warehouse in December 2023, creating a A$30bn group; the merger was valued at A$8.8bn.
  • Share performance: Sigma’s stock has more than tripled in value since the merger announcement.

Strategic implications for Australian and UK pharmacy markets

The withdrawal underscores Sigma’s decision to concentrate on growth opportunities within Australia rather than pursuing a transformational overseas expansion. For Boots, the exit prolongs a period of uncertainty that began when the chain was first put up for sale in 2022. Its current owner, Walgreens Boots Alliance, was acquired by US private‑equity firm Sycamore Partners last year, and other potential buyers—including the UK‑based Weston family—remain in the mix.

What’s next for Sigma and Boots?

Analysts expect Sigma to double‑down on its domestic pipeline, leveraging recent acquisitions and organic growth in the Australian market. Meanwhile, Boots will likely continue courting alternative suitors, with the Weston family and other private‑equity groups positioned as the most plausible candidates. The next few months should reveal whether a new buyer emerges or if the UK chain remains under Sycamore’s stewardship.